About
The group explores personalized breast cancer (BC) hormone therapy via stratified endocrine treatment approaches and genetic risk stratification using large consortial data. It further investigates tumour heterogeneity through spatial immunofluorescence/transcriptomics, and AI-driven computational pathology. In clinical investigations treatment failure is predicted on the basis of somatic signatures (mRNA classifiers, driver mutations), computational features, and circulating tumour markers. International and interdisciplinary collaborations support patient recruitment, genetic validation, and multianalyte assays for the assessment of recurrence risk.